Athenex's actinic keratosis ointment meets in pair of Phase III trials

Athenex Inc. (NASDAQ:ATNX) said KX2-391 (KX-01) met the primary endpoint of improving the proportion of patients who achieved complete clearance

Read the full 203 word article

User Sign In